Practical Hematologist is pleased to present a complimentary webinar. Join us for this educational event and earn 1.0 LIVE CME, CPE, or CNE credit hour.
CHOOSE FROM ONE OF THE FOLLOWING SESSIONS Click the appropriate button below to register
Hanny Al-Samkari, MD Classical Hematologist and Clinical Investigator
Co-Director, Hereditary Hemorrhagic Telangiectasia Center
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Michele P. Lambert, MD, MSTR Medical Director, Special Coagulation Laboratory
Attending Physician, Division of Hematology
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania
Program Overview
The overall goal of immune thrombocytopenia (ITP) treatment is to reduce platelet and megakaryocyte destruction via immune modulation or splenectomy, or to increase megakaryocyte platelet production via thrombopoietin receptor agents. To facilitate treatment decisions, it is critical that adult and pediatric clinicians are knowledgeable about ITP pathophysiology. In this activity, two experts will discuss pediatric and adult treatment options, guideline recommendations and evidence supporting best practice, and strategies for engaging in shared decision-making.
This program will conclude with a live question and answer session. Don’t miss the opportunity to ask your questions or share your clinical challenges directly with the experts.
Agenda
25 minutes
Pediatric ITP Diagnosis and Management
25 minutes
Adult ITP Diagnosis and Management
10 minutes
Audience Q & A
Target Audience
This activity is designed for clinicians who specialize in adult and pediatric hematology, as well as emergency room clinicians and hospitalists.
Learning Objectives Upon completion of this educational activity, participants should be able to:
Review the pathophysiology of ITP and the various mechanisms that can be targeted to treat this condition in adult and pediatric patients
Apply current guideline recommendations for the treatment of pediatric and adult ITP, including the addition of recently approved agents, to practice
Discuss emerging agents that are currently being developed for ITP and how these agents may be integrated into practice as each is approved
Select ITP therapy that is designed to optimize long-term outcomes, patient preferences, and adherence
Accreditation
CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-22-024-L01-P. Knowledge-based
CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
NURSING Credit
MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-024-160
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Faculty Disclosures
Dr. Hanny Al-Samkari has relevant financial relationships related to consulting activities from Agios, Inc., argenx, Dova Pharmaceuticals/Swedish Orphan Biovitrum AB, Forma Therapeutics, Inc., Moderna, Inc., Novartis AG, and Rigel Pharmaceuticals, Inc. His institution has received research funding from Agios, Inc., Amgen Inc., and Dova Pharmaceuticals/Swedish Orphan Biovitrum AB.
Dr. Michele Lambert has relevant financial relationships related to consulting activities from argenx, Dova Pharmaceuticals/Swedish Orphan Biovitrum AB, Janssen Pharmaceuticals, Inc., Novartis AG, Principia Biopharma, Rigel Pharmaceuticals, Inc., Sanofi, and Shionogi Inc. She is an advisory board member for Dova Pharmaceuticals, Octapharma USA, Inc., Principia Biopharma, Rigel Pharmaceuticals, Inc., and Shionogi Inc. Dr. Lambert has received research funding from argenx, Dova Pharmaceuticals, Novartis AG, Octapharma USA, Inc., Principia Biopharma, Rigel Pharmaceuticals, Inc., and Sysmex.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience the discussion of off-label or investigational uses of products or devices.
Planning Committee
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Instructions for Participation and Credit
There are no fees for participating in this activity.
In order to receive credit, all participants must complete the self-assessment post-test and Activity Evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.
CME and CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.
CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation
If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x114 or [email protected].
